Cue biopharma.
Age : 64. Linked companies : Cue Biopharma, Inc. Summary. Pat Nasshorn is Chief Business Officer for Cue Biopharma, Inc. In the past she was Executive-in-Residence at Care Capital LLC. She received an undergraduate degree and an MBA from Temple University (Pennsylvania). Current positions of Pat Nasshorn.
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s ...This work is essential for understanding and, ultimately, targeting, cancer resistance and recurrence. ### Competing Interest Statement KJP is a consultant for CUE Biopharma, Inc. and holds equity interest in Keystone Biopharma, Inc. SRA holds equity interest in Keystone Biopharma, Inc. * PACC : polyaneuploid cancer cellCue Biopharma, Inc. (CUE) shares soared 6.5% in the last trading session to close at $6.70. The move was backed by solid volume with far more shares changing hands than in a normal session.HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Insight – 2022 report provide comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and ...
About us. Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within ...Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware. 001-38327. 47-3324577 (State or other jurisdiction. of incorporation) (Commission. File Number) (IRS Employer. Identification No.) 40 Guest Street. Boston, Massachusetts. 02135 (Zip Code)About Cue Biopharma, Inc. Cue Biopharma is a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body. Our proprietary Immuno-STAT™ (Selective Targeting and Alteration of T Cells) platform is engineered to selectively engage and …
HLP serves as an advisor to and owns stock in Cerberus Therapeutics. HLP serves as a consultant to Johnson and Johnson, Immatics Therapeutics, Cue Biopharma, Revela Therapeutics, and Tiba Bio. JEB reports personal fees from Scorpion Therapeutics, Reactive therapeutics and Olema Oncology; and research grants from Novartis.BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate...
May 25, 2023 · Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the ... Apr 12, 2023 · About Cue Biopharma Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells ... CUE-101 CUE-101 is Cue Biopharma’s lead drug product candidate currently being evaluated for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. Signal #1 incorporates the HPV E7 protein, harbored by HPV-induced cancer cells, and Signal #2 consists of the engineered IL-2 variant. As such, it is designed to activate and expand […]Jan 7, 2021 · Financially, Cue is strong and management has the right early-stage expertise making Cue Biopharma a "buy" at a 1-year price target of $15.60 (+27% upside) and a 5-year price target of $52.50 ... Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the ...
Cue Biopharma, Inc. (“we,” “us,” “our,” “Cue” and the “Company”) was incorporated in the State of Delaware on December 31, 2014 under the name Imagen Biopharma, Inc., and completed its organization, formation and initial capitalization activities effective as of January 1, 2015. In October 2016, the Company changed its name ...
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body to ...
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s ...sored by Cue Biopharma. Trial Registration ClinicalTrials.gov NCT03978689 REFERENCES 1. Quayle SN, Girgis N, Thapa DR, et al. CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc fusion protein, enhances tumor antigen specific T cell activation for the treatment of HPV16-driven malignancies. Clin Cancer Res 2020;26:1953–64.Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s ...Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s ...Cue Biopharma 40 Guest Street Boston, MA 02135 TEL 617-949-2680 . Business Development: [email protected] Media: [email protected] Investor Relations: [email protected] 1, 2023 · 3 Wall Street analysts have issued 12 month price targets for Cue Biopharma's stock. Their CUE share price targets range from $8.00 to $10.00. On average, they predict the company's share price to reach $8.67 in the next year. This suggests a possible upside of 275.2% from the stock's current price. The authors introduce fast analytical screening technique (FAST) chemistry-enabled fine-needle aspiration, which is being developed to allow rapid, multiplex cytometry and inform immunotherapy treatm...
Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware. 001-38327. 47-3324577 (State or other jurisdiction. of incorporation) (Commission. File Number) (IRS Employer. Identification No.) 40 Guest Street. Boston, Massachusetts. 02135 (Zip Code)0001645460http://fasb.org/us-gaap/2021-01-31#LicenseMemberfalsehttp://fasb.org/us-gaap/2021-01-31#LicenseMemberhttp://fasb.org/us-gaap/2021-01-31#LicenseMember--12 ...Cue Biopharma believes its new, elegant approach to modulating the human immune system has the potential to transform the way cancer is treated and significantly improve patients’ lives. We are aiming to build a world-class team of experts to help us advance our research and clinical development programs. Interactive chart of historical net worth (market cap) for Cue Biopharma (CUE) over the last 10 years. How much a company is worth is typically represented ...P.O. BOX 8016, CARY, NC 27512-9903 Cue Biopharma, Inc. Important Notice Regarding the Availability of Proxy Materials Stockholders Meeting to be held on June 7, 2023 For Stockholders of record on April 12, 2023 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet.
Cue BiopharmaAbout CUE. Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases.
22 Feb 2023 ... (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate ...The majority of newly diagnosed oropharyngeal squamous cell carcinoma (OPSCC) is associated with human papillomavirus (HPV) infection, portending very good prognosis, particularly for low-risk patients with nonbulky tumors and minimal smoking history. 1,2 Treatment guidelines from ASCO, the American Society for Radiation …Results. As of Jan 21, 2022, 127 pts (median age of 67 years; n=110 male) received DS-7300 (72 in dose escalation; 55 in dose expansion). Pts had a median 5 prior lines of therapy (range, 1-14). Treatment duration range was 0.1-54 weeks with 51 pts (40%) on treatment. Responses were observed in 30/91 evaluable pts (33%) in total (eg, 7/9 pts ...Conflict of Interest Disclosures. Francis P. Worden reports grants from Bristol-Meyers Squibb, Merck & Company, Cue Biopharma, Eisai, Eli Lilly, Loxo Oncology, and Pfizer and personal fees from Merck & Company, Cue Biopharma, Bayer, and Loxo Oncology, all outside the submitted work.Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) ...Cue Biopharma’s opportunity in autoimmunity and inflammation is centered on two key approaches: Antigen-specific approach (CUE-300 Series): Focuses on diseases with well characterized autoantigens – Cue Biopharma’s Immuno-STAT biologics are engineered to directly modulate the antigen-specific overreactive T cells that attack self-tissue. BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate...• CUE-102-01 is open and enrolling as of June 14, 2022. ACKNOWLEDGEMENTS: The authors would like to thank all the patients participating in this trial as well as their families and caregivers. Many ths also. ank to the investigators and study personnel for their hard work in support of this study. This study is sponsored by Cue Biopharma Inc. andCue Biopharma has a second asset, CUE-102, targeting Wilms Tumor 1, which has shown evidence of activity in early trials. However, the data did not impress investors much, and the stock is trading ...CUE-101 CUE-101 is Cue Biopharma’s lead drug product candidate currently being evaluated for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. Signal #1 incorporates the HPV E7 protein, harbored by HPV-induced cancer cells, and Signal #2 consists of the engineered IL-2 variant. As such, it is designed to activate and expand […]
Cue Biopharma 40 Guest Street Boston, MA 02135 TEL 617-949-2680. Business Development: [email protected] Media: [email protected] Investor Relations: [email protected] .
Cue Biopharma 40 Guest Street Boston, MA 02135 TEL 617-949-2680. Business Development: [email protected] Media: [email protected] Investor Relations: [email protected] .
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted ...CUE-101 CUE-101 is Cue Biopharma’s lead drug product candidate currently being evaluated for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. Signal #1 incorporates the HPV E7 protein, harbored by HPV-induced cancer cells, and Signal #2 consists of the engineered IL-2 variant. As such, it is designed to activate and expand […]News Releases. BOSTON , Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company …13 Nov 2023 ... Cue Biopharma shares encouraging results from Phase 1 studies for CUE-101 for Head and Neck Cancer, and CUE-102 for Wilms' Tumor 1 related ...BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), for CUE-401, a bispecific ...Theravance Biopharma News: This is the News-site for the company Theravance Biopharma on Markets Insider Indices Commodities Currencies StocksBOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable …27 Nov 2023 ... Cue Biopharma operates as pharmaceutical company. The company develops biologic drugs for human immune system to treat cancers and autoimmune ...Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s ...
Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call.Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human ...Cue Biopharma, Inc. (NASDAQ:NASDAQ:CUE) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ETCompany ParticipantsDan Passeri - Chief Executive...Matteo Levisetti brings extensive experience leading global clinical development for mid and large-size pharmaceutical companies. Prior to joining Cue Biopharma, Matteo served as Chief Medical Officer at DNAtrix directing and managing clinical operations and regulatory strategy for several clinical trials. Matteo also served as Chief Medical Officer at Dauntless Pharmaceuticals where he was ...Instagram:https://instagram. wendy salesbug holdingsppg priceletter postage cost 3 Wall Street analysts have issued 12 month price targets for Cue Biopharma's stock. Their CUE share price targets range from $8.00 to $10.00. On average, they predict the company's share price to reach $8.67 in the next year. This suggests a possible upside of 275.2% from the stock's current price. hedge fund real estatemasseter botox insurance Get the latest Sana Biotechnology Inc (SANA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. best fixed income investments 2023 0001645460http://fasb.org/us-gaap/2021-01-31#LicenseMemberfalsehttp://fasb.org/us-gaap/2021-01-31#LicenseMemberhttp://fasb.org/us-gaap/2021-01-31#LicenseMember--12 ...Cue Biopharma last announced its earnings data on November 9th, 2023. The reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.06. The business earned $2.10 million during the quarter, compared to analyst estimates of $1.49 million.